NCM to collaborate with Genentech

PET radiopharmaceutical developer NCM USA said it has signed a technology development and supply agreement with Genentech.

From its New York City-based manufacturing site, NCM will supply PET radiopharmaceuticals, including zirconium-89 (Zr-89), for use as imaging agents in some Genentech clinical trials, according to the firm.

Page 1 of 435
Next Page